4.68
price up icon0.00%   0.02
 
loading
전일 마감가:
$4.70
열려 있는:
$4.67
하루 거래량:
10,880
Relative Volume:
0.10
시가총액:
$15.10M
수익:
-
순이익/손실:
$-37.68M
주가수익비율:
-0.3954
EPS:
-11.8364
순현금흐름:
$-30.65M
1주 성능:
-3.69%
1개월 성능:
-16.37%
6개월 성능:
-73.95%
1년 성능:
+985.45%
1일 변동 폭
Value
$4.60
$4.73
1주일 범위
Value
$4.42
$4.92
52주 변동 폭
Value
$0.3502
$20.00

Passage Bio Inc Stock (PASG) Company Profile

Name
명칭
Passage Bio Inc
Name
전화
(267) 866-0312
Name
주소
ONE COMMERCE SQUARE, PHILADELPHIA, PA
Name
직원
24
Name
트위터
@passage_bio
Name
다음 수익 날짜
2026-08-11
Name
최신 SEC 제출 서류
Name
PASG's Discussions on Twitter

Compare PASG vs VRTX, REGN, ARGX, ALNY, RVMD

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
PASG icon
PASG
Passage Bio Inc
4.70 15.04M 0 -37.68M -30.65M -11.84
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
520.41 134.02B 12.34B 4.34B 3.71B 16.87
REGN icon
REGN
Regeneron Pharmaceuticals Inc
669.27 68.59B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
924.21 58.44B 4.16B 1.29B 734.26M 19.58
ALNY icon
ALNY
Alnylam Pharmaceuticals Inc
318.82 41.76B 4.29B 577.22M 641.34M 4.2086
RVMD icon
RVMD
Revolution Medicines Inc
189.90 40.23B 742.00K -1.37B -1.07B -7.0731

Passage Bio Inc Stock (PASG) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2026-04-21 다운그레이드 Chardan Capital Markets Buy → Neutral
2026-04-21 다운그레이드 TD Cowen Buy → Hold
2026-04-21 다운그레이드 Wedbush Outperform → Neutral
2026-03-31 개시 Oppenheimer Outperform
2026-02-10 재개 Chardan Capital Markets Buy
2024-11-29 재개 Wedbush Outperform
2024-09-03 개시 Rodman & Renshaw Buy
2022-03-08 다운그레이드 JP Morgan Overweight → Neutral
2022-01-19 다운그레이드 Goldman Buy → Neutral
2021-07-01 개시 Raymond James Outperform
2021-06-15 개시 BTIG Research Buy
2021-03-04 업그레이드 Goldman Neutral → Buy
2021-02-04 개시 Guggenheim Buy
2021-01-25 개시 Wedbush Outperform
2021-01-04 업그레이드 JP Morgan Neutral → Overweight
2020-12-11 개시 Citigroup Neutral
2020-08-14 다운그레이드 JP Morgan Overweight → Neutral
2020-06-25 다운그레이드 Goldman Buy → Neutral
2020-03-25 개시 Chardan Capital Markets Buy
2020-03-24 개시 Cowen Outperform
2020-03-24 개시 Goldman Buy
2020-03-24 개시 JP Morgan Overweight
모두보기

Passage Bio Inc 주식(PASG)의 최신 뉴스

pulisher
Jun 30, 2026

Latham & Watkins Advises Remix Therapeutics in Merger With Passage Bio - Legal Desire Media and Insights

Jun 30, 2026
pulisher
Jun 29, 2026

Passage Bio (PASG) holder adds 50,055 shares in open-market buy - Stock Titan

Jun 29, 2026
pulisher
Jun 29, 2026

Passage Bio to Merge With Remix in Deal Backed by $100 Million Financing - MyChesCo

Jun 29, 2026
pulisher
Jun 26, 2026

Passage Bio, Inc. Actuals & Estimates (NASDAQ:PASG) - TradingView

Jun 26, 2026
pulisher
Jun 26, 2026

Enterprise value to EBIT forward of Passage Bio, Inc. – NASDAQ:PASG - TradingView

Jun 26, 2026
pulisher
Jun 26, 2026

Layoff Tracker: Biogen axes ‘small number’ of Apellis roles after $5.6B buy - BioSpace

Jun 26, 2026
pulisher
Jun 26, 2026

Price to sales forward of Passage Bio, Inc. – NASDAQ:PASG - TradingView

Jun 26, 2026
pulisher
Jun 26, 2026

Price to book forward of Passage Bio, Inc. – NASDAQ:PASG - TradingView

Jun 26, 2026
pulisher
Jun 26, 2026

Price to earnings forward of Passage Bio, Inc. – NASDAQ:PASG - TradingView

Jun 26, 2026
pulisher
Jun 26, 2026

Passage Bio, Inc. Actuals & Estimates (BOATS:PASG) - TradingView

Jun 26, 2026
pulisher
Jun 25, 2026

Baselake Partners (PASG) reports 235,058 shares, 7.3% ownership - Stock Titan

Jun 25, 2026
pulisher
Jun 25, 2026

Remix Therapeutics secures $100M and a reverse merger - The Business Journals

Jun 25, 2026
pulisher
Jun 25, 2026

12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga

Jun 25, 2026
pulisher
Jun 25, 2026

Remix to go public in reverse merger with once high-flying Passage Bio - BioPharma Dive

Jun 25, 2026
pulisher
Jun 25, 2026

PASG Forecast — Price Target — Prediction for 2027 - TradingView

Jun 25, 2026
pulisher
Jun 25, 2026

12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga

Jun 25, 2026
pulisher
Jun 25, 2026

Remix to enter Nasdaq through Passage Bio reverse merger - The Pharma Letter

Jun 25, 2026
pulisher
Jun 25, 2026

Passage Bio and Remix Therapeutics Announce Merger to Advance RNA-Targeted Cancer Therapies with $100M Financing – Minichart - Minichart

Jun 25, 2026
pulisher
Jun 24, 2026

SPRY, PASG, BOXL: Why These Stocks Plunged Double Digits In After-Hours Trading Today - TradingView

Jun 24, 2026
pulisher
Jun 24, 2026

SGMOQ Stock Price and Chart — OTC:SGMOQ - TradingView

Jun 24, 2026
pulisher
Jun 24, 2026

PASG Stock Slumps 16% After-Hours — What’s Driving The Selloff? - Asianet Newsable

Jun 24, 2026
pulisher
Jun 24, 2026

Stocks to Watch: Micron, ARS Pharmaceuticals, MillerKnoll, Passage Bio - Moomoo

Jun 24, 2026
pulisher
Jun 24, 2026

Passage Bio Shares Slide on Merger With Remix Therapeutics - Moomoo

Jun 24, 2026
pulisher
Jun 24, 2026

Passage Bio And Remix Therapeutics Announce Merger Agreement - TradingView

Jun 24, 2026
pulisher
Jun 24, 2026

Passage Bio (PASG) Slides 3.9% as Momentum Falters Near Key SupportWave Truncation - dars.gov.et

Jun 24, 2026
pulisher
Jun 24, 2026

Passage Bio (PASG) to merge with Remix; Remix private placement tops $100M - Stock Titan

Jun 24, 2026
pulisher
Jun 24, 2026

Passage Bio to merge with Remix Therapeutics in all-stock deal - Investing.com

Jun 24, 2026
pulisher
Jun 24, 2026

9 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga

Jun 24, 2026
pulisher
Jun 24, 2026

Passage Bio to Merge With Remix Therapeutics; Remix Valued at $226M, $100M Financing - TradingView

Jun 24, 2026
pulisher
Jun 24, 2026

Passage Bio (PASG) to combine with Remix; Remix valued at $226M, $100M raise - Stock Titan

Jun 24, 2026
pulisher
Jun 24, 2026

Passage Bio | 425: Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactionsmoomoo - Moomoo

Jun 24, 2026
pulisher
Jun 24, 2026

Remix Therapeutics to reverse-merge with Passage Bio (PASG) and raise $100M - Stock Titan

Jun 24, 2026
pulisher
Jun 24, 2026

Press Release: Passage Bio and Remix Therapeutics Announce Merger Agreement - Moomoo

Jun 24, 2026
pulisher
Jun 24, 2026

PASG Stock Slumps 16% After-HoursWhat's Driving The Selloff? - Mena FN

Jun 24, 2026
pulisher
Jun 23, 2026

Remix Therapeutics, Inc. entered into a definitive merger agreement to acquire Passage Bio, Inc. in a reverse merger transaction for approximately $230 million. - marketscreener.com

Jun 23, 2026
pulisher
Jun 23, 2026

Passage Bio Inc (PASG) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Jun 23, 2026
pulisher
Jun 18, 2026

Passage Bio Inc (PASG) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

Jun 18, 2026
pulisher
Jun 17, 2026

Passage Bio Inc (PASG) Valuation: PE, PB & Fair Value Analysis - TradingKey

Jun 17, 2026
pulisher
Jun 17, 2026

Passage Bio Inc (PASG) Financial Health: Profitability & Balance Sheet Analysis - TradingKey

Jun 17, 2026
pulisher
Jun 17, 2026

Passage Bio Inc (PASG) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

Jun 17, 2026
pulisher
Jun 17, 2026

Passage Bio Inc (PASG) Institutional Confidence - TradingKey

Jun 17, 2026
pulisher
Jun 17, 2026

Passage Bio Inc (PASG) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

Jun 17, 2026
pulisher
Jun 17, 2026

Passage Bio Inc (PASG) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey

Jun 17, 2026
pulisher
Jun 17, 2026

Passage Bio Inc (PASG) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Jun 17, 2026
pulisher
Jun 16, 2026

Sea Limited’s Shopee Order Growth Reinforces E-Commerce MomentumEarnings Momentum Score - newsline.com

Jun 16, 2026
pulisher
Jun 12, 2026

PRS Q1 2026 Earnings: Solid EPS Beat Driven by Core OperationsEarnings Deceleration Risk - newsline.com

Jun 12, 2026
pulisher
Jun 11, 2026

Passage Bio Inc. (PASG) Surges Over 9% as Biotech Stock Tests Key ResistanceEarnings Quality Factor - newsline.com

Jun 11, 2026
pulisher
Jun 11, 2026

Gartner (IT) Q1 2026 Earnings: EPS Surprises to the Upside Despite Modest Stock PullbackRevenue Recognition Risk - newsline.com

Jun 11, 2026
pulisher
Jun 11, 2026

Fierce Biotech Layoff Tracker 2026: Genentech trims R&D; Neumora cuts 35% - Fierce Biotech

Jun 11, 2026
pulisher
Jun 10, 2026

Guggenheim Downgrades Passage Bio(PASG.US) to Hold Rating - Moomoo

Jun 10, 2026
pulisher
Jun 10, 2026

Passage Bio (PASG) Downgraded to Neutral as Strategic Review Ini - GuruFocus

Jun 10, 2026

Passage Bio Inc (PASG) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading

Passage Bio Inc 주식 (PASG) 내부자 거래

내부자 거래 관계 날짜 거래 비용 #주식 가치 ($) #주식 총계
Chou William
PRESIDENT AND CEO
Jan 08 '26
Sale
18.44
4,076
75,159
6,524
Borthwick Kathleen
CFO
Jan 08 '26
Sale
18.44
2,062
38,022
5,402
$112.78
price up icon 0.82%
$35.27
price up icon 0.23%
$58.06
price up icon 1.79%
ONC ONC
$305.00
price down icon 0.85%
$82.23
price up icon 0.32%
$190.47
price up icon 0.31%
자본화:     |  볼륨(24시간):